Food and Drug Administration (FDA) Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

JAMA Internal Medicine : Flibanserin for Hypoactive Sexual Desire Disorder in Women
Interview with Ellen T. M. Laan, PhD, author of Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-Analysis, and Steven Woloshin, MD, MS, author of US Food and Drug Administration Approval of Flibanserin: Even the Score Does Not Add Up (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - February 29, 2016 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts

Clinical Trial Participant Discusses Approval of New Myeloma Treatment From a Patient Perspective
The second monoclonal antibody for myeloma, elotuzumab (Empliciti) was approved today by the U.S. Food and Drug Administration for use in combination with two other therapies to treat people with mult... Author: P2Professional Added: 12/03/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 3, 2015 Category: Cancer & Oncology Source Type: podcasts

Clinical Trial Participant Discusses Approval of New Myeloma Treatment From a Patient Perspective
The second monoclonal antibody for myeloma, elotuzumab (Empliciti) was approved today by the U.S. Food and Drug Administration for use in combination with two other therapies to treat people with mult... Author: patientpower Added: 12/03/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 3, 2015 Category: Cancer & Oncology Source Type: podcasts

FDA Drug Safety Podcast: FDA advises of rare cases of underactive thyroid in infants given iodine-containing contrast agents for medical imaging
On November 17, 2015, FDA announced it is advising that rare cases of underactive thyroid have been reported in infants following the use of contrast media containing iodine, also called “contrast dye,” for X-rays and other medical imaging procedures. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - November 30, 2015 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

FDA Drug Safety Podcast: FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death
On November 6, 2015 FDA announced that a review has determined that long-term use of the blood-thinning drug Plavix (active ingredient clopidogrel) does not increase or decrease overall risk of death in patients with, or at risk for, heart disease. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - November 10, 2015 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

FDA Drug Safety Podcast: FDA review found no increased cardiovascular risks with Parkinson’s disease drug entacapone
On October 26, 2015 FDA announced an FDA safety review has found no clear evidence of an increased risk of heart attacks, stroke, or other cardiovascular events associated with the use of entacapone for the treatment of Parkinson’s disease. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - November 6, 2015 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

FDA Drug Safety Podcast: FDA requires drug interaction studies with potassium-lowering drug Kayexalate (sodium polystyrene sulfonate)
On October 22, 2015, the FDA announced it is requiring the Kayexalate manufacturer to conduct studies to investigate Kayexalate’s potential to bind to other medications administered by mouth – drug interactions that could affect how well the other medications work. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - October 30, 2015 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

FDA Drug Safety Podcast: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie
On October 22, 2015 FDA announced it is warning that hepatitis C treatments Viekira Pak and Technivie can cause serious liver injury mostly in patients with underlying advanced liver disease. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - October 30, 2015 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

October 6 2015 Issue
1) Evaluation of outcome measures for neurogenic claudication and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. John Markman about his paper on a patient-centered approach for evaluation of outcome measures for neurogenic claudication. Dr. Ted Burns is interviewing Dr. Robert Gross for our “What's Trending” feature of the week about Neurology's spoke journals. In the next part of the p...
Source: Neurology Podcast - October 12, 2015 Category: Neurology Authors: American Academy of Neurology Source Type: podcasts

Research Misconduct Identified by the FDA (JAMA Internal Medicine)
Interview with Charles Seife, MS, author of Research Misconduct Identified by the US Food and Drug Administration: Out of Sight, Out of Mind, Out of the Peer-Reviewed Literature (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - February 9, 2015 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts

JAMA Internal Medicine : Research Misconduct Identified by the FDA
Interview with Charles Seife, MS, author of Research Misconduct Identified by the US Food and Drug Administration: Out of Sight, Out of Mind, Out of the Peer-Reviewed Literature (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - February 9, 2015 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts

Clinical Trial Design & Development of Highly Targeted Agents in the Molecular Era
http://cancerGRACE.org/... Acquired Resistance Forum Video #5: Dr. Gideon Blumenthal of the US Food and Drug Administration (FDA) discussed the FDA process for approving targeted therapies. GRACEca... Author: cancergrace Added: 10/15/2014 (Source: Oncology Tube)
Source: Oncology Tube - October 15, 2014 Category: Cancer & Oncology Source Type: podcasts

A New Oral CLL and SLL Treatment: What Could It Mean for Patients?
The Food and Drug Administration (FDA) recently approved idelalisib (Zydelig), a new oral inhibitor therapy to treat CLL and SLL. Patients now have another option that may spare them the need for chem... Author: patientpower Added: 08/03/2014 (Source: Oncology Tube)
Source: Oncology Tube - August 4, 2014 Category: Cancer & Oncology Source Type: podcasts